In early 2026, the U.S. Supreme Court (the “Court”) agreed to hear a case at the heart of pharmaceutical intellectual property that could have significant implications for the manufacturers of both ...

As one long-running feud over the controversial generic drug carveout known as “skinny” labeling comes to a close, the United States’ top lawyer is urging the Supreme Court to reverse a recent ...

Vascepa is an omega-3 fatty acid also known as icosapent ethyl. Doctors prescribe it to adults with certain conditions to lower their blood triglyceride levels and help reduce the risk of heart ...

WASHINGTON, Jan 16 (Reuters) - The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic ...

Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with ...

The Supreme Court on Jan. 16, 2026, agreed to decide a case about how generic companies can communicate to the market about their products, including whether their product promotion may infringe ...

In 2025, Amarin's net loss per share was $0.09, significantly better than the $0.20 reported in 2024. This progress, despite ...

The Supreme Court may soon address a recent, pivotal case involving the use of “skinny labels” to avoid inducing infringement in pharmaceutical patent infringement cases. The outcome could clarify ...

The Company continued to focus on its commercialization strategy for VASCEPA/VAZKEPA in the mature U.S. market and early-stages in Europe and Rest of World (RoW). The following is a summary of select ...

Jan 21 (Reuters) - Amarin Corp Plc's shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood ...